Greenad Spółka z Ograniczoną Odpowiedzialnością (KRS 0000877611, NIP 9452241066) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. GREENAD operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since January 11, 2021.
Historical suspension of activities
Suspension: June 1, 2022 - resumed: June 2, 2025
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Greenad
Identity
- Name
- Greenad Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- January 11, 2021
- Registry status as of
- December 3, 2025
- Latest entry
- July 20, 2025
- Founding act
- 06.01.2021
Articles of association history (1)
- January 6, 2021: 06.01.2021
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. NA ZIELONKI, 15, 3, 31-270, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- ANNA.KOSIOROWSKA.KRK@GMAIL.COM
- Website
- -
- E-delivery address
- Not disclosed in the registry
Operational status - Greenad
Founded
January 11, 2021
5 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
99 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
N/A
Registry entries
17
latest: July 20, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Greenad.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
